# Contents of a Complete Submission for the Evaluation of Proprietary Names - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/contents-of-a-complete-submission-for-the-evaluation-of-proprietary-names/8bbe789c-b7fd-4a76-9e78-6ea3344719df

> FDA guidance document: Contents of a Complete Submission for the Evaluation of Proprietary Names. Issue date: April 11, 2016. Get complete insights and analysis.

---

## Details

- Title: Contents of a Complete Submission for the Evaluation of Proprietary Names
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2016-04-11
- Last Changed: 2025-02-03
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2008-D-0592">FDA-2008-D-0592</a>

## Related Documents

- [Scientific Considerations in Demonstrating Biosimilarity to a Reference Product](https://www.globalkeysolutions.net/guidances/guidance-document/scientific-considerations-in-demonstrating-biosimilarity-to-a-reference-product/b98b0335-f4b7-4a14-88b1-7ea4d02c7e37)
- [Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/q7-good-manufacturing-practice-guidance-for-active-pharmaceutical-ingredients-guidance-for-industry/4c33ca12-225d-4a88-aaa5-3f0f8357fdd9)
- [E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)](https://www.globalkeysolutions.net/guidances/guidance-document/e2cr2-periodic-benefit-risk-evaluation-report-pbrer/34160d8d-51b7-47bd-a753-e6ad93180322)